Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지
DOI QR코드

DOI QR Code

Inhibitory Effects of Banhasasim-tang Extracts on Cisplatin-induced Nephrotoxicity in Mouse Model

시스플라틴 유도 신장 독성에 대한 반하사심탕 추출물의 방어효과

  • Oh, Gi Su (Center for Metabolic Function Regulation, School of Medicine, Wonkwang University) ;
  • Lee, Su Bin (Center for Metabolic Function Regulation, School of Medicine, Wonkwang University) ;
  • So, Hong Seob (Center for Metabolic Function Regulation, School of Medicine, Wonkwang University) ;
  • Kim, Ha Rim (Center for Metabolic Function Regulation, School of Medicine, Wonkwang University) ;
  • Lee, Young Rae (Department of Oral Biochemistry, School of Dentistry, Wonkwang University) ;
  • Lee, Geum San (Department of Herbology, School of Korean Medicine, Wonkwang University) ;
  • Yang, Sei Hoon (Department of Internal Medicine, School of Medicine, Wonkwang University) ;
  • Lim, Chan Han (Department of Physiology, School of Korean Medicine, Wonkwang University) ;
  • Kwon, Kang Beom (Department of Physiology, School of Korean Medicine, Wonkwang University)
  • 오기수 (원광대학교 의과대학 대사기능제어연구센터) ;
  • 이수빈 (원광대학교 의과대학 대사기능제어연구센터) ;
  • 소홍섭 (원광대학교 의과대학 대사기능제어연구센터) ;
  • 김하림 (원광대학교 의과대학 대사기능제어연구센터) ;
  • 이영래 (원광대학교 치과대학 구강생화학교실) ;
  • 이금산 (원광대학교 한의과대학 본초학교실) ;
  • 양세훈 (원광대학교 의과대학 내과학교실) ;
  • 임찬한 (원광대학교 한의과대학 생리학교실) ;
  • 권강범 (원광대학교 한의과대학 생리학교실)
  • Received : 2018.04.17
  • Accepted : 2018.10.24
  • Published : 2018.10.25
Download PDF
⟨ Previous Next ⟩

Abstract

In this study, Banhasasim-tang extracts (BSTE) have an inhibitory effects on cisplatin-induced nephrotoxicity in mouse model. Cisplatin is the most widely used anticancer drug for treatment of various cancer. However, cisplatin treatment to cancer patients leads to many side effects such as nephrotoxicity and body weight decrease. We hypothesize that BSTE improve the cisplatin-induced side effects in mouse model. We found that BSTE administration protected tubular injury by cisplatin in mouse model. BSTE also inhibited increase of creatinine and BUN induced by cisplatin injection in serum. Collectively, our data suggest that BSTE could be a therapeutic agent for reducing kidney injury induced by cisplatin treatment in cancer patients.

Keywords

References

  1. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rorth M, Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007;130:1076-88.
  2. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and strategies. Kidney Int. 2008;73:994-1007. https://doi.org/10.1038/sj.ki.5002786
  3. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007;7:573-84. https://doi.org/10.1038/nrc2167
  4. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 2014;740:364-78. https://doi.org/10.1016/j.ejphar.2014.07.025
  5. Nicolao P, Giometto B. Neurological toxicity of ifosfamide. Oncology 2003;65:11-6. https://doi.org/10.1159/000073352
  6. Ju SM, Kim SH, Kim YM, Jeon BH, Kim WS. Machanism of Cisplatin-induced Apoptosis and Bojungbangam-tang-mediated Antiapoptotic Effect on Cell Proliferation in Rat Mesangial Cells. Korean J Oriental Physiology & Pathology 2013;27:43-8.
  7. Kim DG, Kim KJ, Ju SM, Kim YI, Choi HS, Keum KS, Kim WS, Gao YA, Jeon BH. Protective effect of Ganopoly and Ganopoly/C+ on nephrotoxicity induced by cisplatin in rats. Korean J Oriental Physiology & Pathology 2003;17:316-25.
  8. Kim JY, Kim CH. Effect of Zizyphi Spinosae Extract on Cisplatin and t-Butylhydroperoxide Induced Acute Renal Failure in Rabbits. Journal of Life Science 2014;24:777-83. https://doi.org/10.5352/JLS.2014.24.7.777
  9. Zhang ZJ. Shanghanzabinglun, Han dinasty, 200-210: hanhanlun. Seoul:Daesungmunhwasa; 1993. 112 p.
  10. Heo, J. Donguibogam, Namsandang, Seoul, 2007. p 397.
  11. Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC. High-dose cisplatin in hypertonic saline. Ann. Intern. Med. 1984;100:19-24. https://doi.org/10.7326/0003-4819-100-1-19
  12. Gandara DR, Perez EA, Phillips WA, Lawrence HJ, DeGregorio M. Evaluation of cisplatin dose intensity: current status and future prospects. Anticancer Res. 1989;9:1121-8.
  13. Oriana S, Bohm S, Spatti G, Zunino F, Di Re F. A preliminary clinical experience with reduced glutathione as protector against cisplatintoxicity. Tumori. 1987;73:337-40. https://doi.org/10.1177/030089168707300403
  14. Aoyama T, Nishikawa K, Takiguchi N, Tanabe K, Imano M, Fukushima R, Sakamoto J, Oba MS, Morita S, Kono T, Tsuburaya A. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. Cancer Chemother. Pharmacol. 2014;73:1047-54. https://doi.org/10.1007/s00280-014-2440-x
  15. Yamashita T1, Araki K, Tomifuji M, Kamide D, Tanaka Y, Shiotani A. A traditional Japanese medicine--Hangeshashinto (TJ-14)--alleviates chemoradiation-induced mucositis and improves rates of treatment completion. Support. Care Cancer. 2015 Jan;23(1):29-35. https://doi.org/10.1007/s00520-014-2315-z
  16. Storck M, Schilling M, Prestel R, Abendroth D, Burkhardt K, Hammer C. Production of proinflammatory cytokines and adhesion molecules in exvivo xenogeneic kidney perfusion. Transplant International 1994;7:647-9. https://doi.org/10.1111/j.1432-2277.1994.tb01464.x
  17. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. Journal of Clinical Investigation 2002;110:835-42. https://doi.org/10.1172/JCI200215606